CYBERMED LIFE - ORGANIC  & NATURAL LIVING

Laser Treatment - Low-Level

Low-level laser therapy ameliorates disease progression in a mouse model of multiple sclerosis.

Written by CYBERMED LIFE NEWS
facebook Share on Facebook
Abstract Title:

Low-level laser therapy ameliorates disease progression in a mouse model of multiple sclerosis.

Abstract Source:

Autoimmunity. 2016 Mar ;49(2):132-42. Epub 2015 Dec 24. PMID: 26703077

Abstract Author(s):

Elaine D Gonçalves, Priscila S Souza, Vicente Lieberknecht, Giulia S P Fidelis, Rafael I Barbosa, Paulo C L Silveira, Ricardo A de Pinho, Rafael C Dutra

Article Affiliation:

Elaine D Gonçalves

Abstract:

Multiple sclerosis (MS) is an autoimmune demyelinating inflammatory disease characterized by recurrent episodes of T cell-mediated immune attack on central nervous system (CNS) myelin, leading to axon damage and progressive disability. The existing therapies for MS are only partially effective and are associated with undesirable side effects. Low-level laser therapy (LLLT) has been clinically used to treat inflammation, and to induce tissue healing and repair processes. However, there are no reports about the effects and mechanisms of LLLT in experimental autoimmune encephalomyelitis (EAE), an established model of MS. Here, we report the effects and underlying mechanisms of action of LLLT (AlGaInP, 660 nm and GaAs, 904 nm) irradiated on the spinal cord during EAE development. EAE was induced in female C57BL/6 mice by immunization with MOG35-55 peptide emulsified in complete Freund's adjuvant. Our results showed that LLLT consistently reduced the clinical score of EAE and delayed the disease onset, and also prevented weight loss induced by immunization. Furthermore, these beneficial effects of LLLT seem to be associated with the down-regulation of NO levels in the CNS, although the treatment with LLLT failed to inhibit lipid peroxidation and restore antioxidant defense during EAE. Finally, histological analysis showed that LLLT blocked neuroinflammation through a reduction of inflammatory cells in the CNS, especially lymphocytes, as well as preventing demyelination in the spinal cord after EAE induction. Together, our results suggest the use of LLLT as a therapeutic application during autoimmune neuroinflammatory responses, such as MS.


We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.